Merck Quarterly Balance Sheet
NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Merck financial position
As of Jun 30, 2026, Merck reported total assets of $129.80 billion, up 10.4% from a year earlier against total liabilities of $87.82 billion. Shareholders' equity stood at $41.93 billion, or 32.3% of assets. The company held $6.85 billion in cash and equivalents against $53.91 billion of debt, a net debt position of $47.06 billion.
The current ratio (current assets divided by current liabilities) was 1.32, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.29.
Summary generated from market data by MetaCap's automated system. Methodology
Merck balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.85B | 5.33B | 14.56B | 18.17B | 8.01B | 8.63B | 13.24B | 14.59B | 11.30B | 5.58B | 6.84B | 8.61B |
| Short-Term Investments | 292.00M | 375.00M | 0 | 45.00M | 615.00M | 599.00M | 447.00M | 0 | 50.00M | 40.00M | 252.00M | 168.00M |
| Receivables | 12.56B | 12.21B | 11.78B | 12.12B | 11.85B | 10.79B | 10.28B | 11.38B | 11.64B | 11.37B | 10.35B | 10.39B |
| Inventory | 6.21B | 6.48B | 6.66B | 6.44B | 6.60B | 6.20B | 6.11B | 6.24B | 6.47B | 6.51B | 6.36B | 6.13B |
| Total Current Assets | 36.68B | 35.02B | 43.52B | 47.56B | 37.06B | 35.50B | 38.78B | 40.36B | 38.20B | 31.45B | 32.17B | 31.95B |
| Property, Plant & Equipment | 25.74B | 25.43B | 25.32B | 25.64B | 25.24B | 24.79B | 23.78B | 23.45B | 23.22B | 23.05B | 23.05B | 22.53B |
| Goodwill | 21.58B | 21.58B | 21.58B | 21.59B | 21.59B | 21.68B | 21.67B | 21.70B | 21.16B | 21.18B | 21.20B | 21.18B |
| Intangible Assets | 24.98B | 25.75B | 26.68B | 15.31B | 15.19B | 15.76B | 16.37B | 17.01B | 16.98B | 17.57B | 18.01B | 19.20B |
| Long-Term Investments | 1.22B | 1.10B | 956.00M | 1.12B | 774.00M | 616.00M | 463.00M | 575.00M | 357.00M | 280.00M | 252.00M | 1.31B |
| Total Assets | 129.80B | 128.69B | 136.87B | 129.55B | 117.52B | 115.12B | 117.11B | 117.53B | 112.63B | 105.85B | 106.67B | 106.73B |
| Accounts Payable | 3.83B | 3.86B | 4.40B | 4.15B | 3.89B | 3.78B | 4.08B | 3.59B | 3.52B | 3.51B | 3.92B | 3.51B |
| Short-Term Debt | 2.83B | 2.44B | 2.59B | 1.41B | 1.43B | 1.36B | 2.65B | 3.15B | 3.07B | 3.08B | 1.37B | 887.00M |
| Total Current Liabilities | 27.73B | 26.95B | 28.33B | 28.63B | 26.04B | 25.17B | 28.42B | 29.59B | 26.06B | 25.10B | 25.69B | 23.09B |
| Long-Term Debt | 51.08B | 46.67B | 46.75B | 39.97B | 33.97B | 33.48B | 34.46B | 34.98B | 34.72B | 31.14B | 33.68B | 33.97B |
| Total Liabilities | 87.82B | 82.75B | 84.20B | 77.64B | 68.46B | 66.72B | 70.73B | 72.97B | 68.98B | 65.42B | 69.04B | 65.43B |
| Shareholders' Equity | 41.93B | 45.88B | 52.61B | 51.85B | 48.99B | 48.34B | 46.31B | 44.50B | 43.58B | 40.36B | 37.58B | 41.25B |
| Retained Earnings | 63.27B | 66.72B | 73.08B | 72.23B | 68.48B | 66.10B | 63.07B | 61.38B | 60.19B | 56.70B | 53.90B | 57.08B |
| Total Debt | 53.91B | 49.12B | 49.34B | 41.37B | 35.40B | 34.84B | 37.11B | 38.13B | 37.79B | 34.22B | 35.05B | 34.86B |
| Net Cash (Debt) | -46.77B | -43.41B | -34.77B | -23.16B | -26.78B | -25.62B | -23.42B | -23.54B | -26.43B | -28.60B | -27.96B | -26.09B |
This table shows 12 quarterly periods of Merck's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow MRK's reporting calendar. What is a balance sheet?